This page will be regularly updated with any developments and new resources and guidance related to TREATMENT of Early-Stage T1 Diabetes.
NICE TA 1176
The NICE TA 1176: Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes, was published on 9th July 2026 with a 90 day implementation period.
https://www.nice.org.uk/guidance/ta1176
Work to support implementation of the NICE TA is developing at pace and all updates, documents and resources will be posted here as they become available. Commissioning information can be found here.
Teplizumab consensus statement
Publications
From Screening to Delivery of Disease- Modifying Therapy (March 2026) – From Screening to Delivery of Disease- Modifying Therapy: Real World Follow- Up of Children With Early- Stage Type 1 Diabetes
Example Standard Operating Procedure
This SOP has been designed to be used as a template within your local services.
Template SOP protocol – September 2026
Example Treatment Pathways
As treatment pathways are developed across the country they will be included in this repository.
We would encourage you to share your pathways with your network lead or directly with Jenny Foster so they can be included.
Example Referral Forms
As treatment pathways and the associated resources are developed across the country they will be included in this repository.
We would encourage you to share your pathways with your network lead or directly with Jenny Foster so they can be included.
Editable Example Early-Stage Type 1 Diabetes Referral Form (Wessex Network)
Business Case Templates
As business cases are developed across the country they will be included in this repository.
We would encourage you to share your business cases with your network lead so they can be included.
Teplizumab Business Case Template